Jia-Pharmaceutical medium-term net profit increased by more than 30% to 10 to 3 to 7 to 1 yuan

NetEase Financial August 4 News Jia should pharmaceutical Wednesday evening released 2010.5 Annual report. In the first half of 2010, the total operating income of Dksh was 39.023 million yuan, which grew 33.42% from a year earlier; operating profit, total profit and net profit were 7.862 million yuan, 8.1619 million yuan and 7.5921 million yuan respectively; increased by 61.65% and 25.51% respectively over a year earlier and 31.33% semi-annual reports show that the pharmaceutical is mainly engaged in the development of proprietary Chinese medicine, production and sales.　　At present, Kerry Pharmaceutical has 5 dosage forms 65 kinds of drugs, of which 48 kinds of OTC varieties, listed in the National Health Insurance catalogue of 26 species.　　Kerry Pharmaceutical is expected, 2010 1-September, the return of the listed company's shareholders net profit of 15% ~30.00%, mainly due to the company's market expansion, the main business income growth, at the same time, the Hunan Jinsha Pharmaceutical Co., Ltd. Long-term equity investment income growth. Profit distribution: Jia-Pharmaceutical said that the company's existing 82 million shares of equity base, to all shareholders 10 shares to send Red shares 3 shares, and send cash 1 yuan (including tax), a total cash dividend of 8.2 million yuan. At the same time, the Capital Provident Fund to all shareholders to 7 shares per 10 shares.　　　　After implementation, the company's total equity increased to 164 million shares, adding 82 million shares. Related topics: Semi-annual report of 2010 listed Companies